ANAVEX LIFE SCIENCES CORP.

AVXL · Nasdaq · SIC 2836: Biological Products, (No Diagnostic Substances)
242
SEC Filings

Business Summary

Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company developing precision medicine therapeutics for central nervous system diseases including Alzheimer's disease, Parkinson's disease, Rett syndrome, schizophrenia, and other neurodegenerative and neurodevelopmental disorders. Its lead compound, ANAVEX 2-73 (blarcamesine), targets sigma-1 and muscarinic receptors and is in multiple clinical trials. A second compound, ANAVEX 3-71, is in one clinical trial. The company uses genomic biomarker analysis and AI-driven machine learning to support precision medicine approaches.

Next Earnings

Q2 FY2026 — expected 2026-07-19

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionAVXLdiscussed_in_filing Artificial Intelligence
topic_mentionAVXLdiscussed_in_filing Cybersecurity
topic_mentionAVXLdiscussed_in_filing Trusted Computing
topic_mentionAVXLdiscussed_in_filing Blockchain & Crypto
topic_mentionAVXLdiscussed_in_filing Autonomous Vehicles
topic_mentionAVXLdiscussed_in_filing Regulation
topic_mentionAVXLdiscussed_in_filing Healthcare & Bio
topic_mentionAVXLdiscussed_in_filing Platform & Ecosystem
topic_mentionAVXLdiscussed_in_filing Sovereign & Government
topic_mentionAVXLdiscussed_in_filing Artificial Intelligence
topic_mentionAVXLdiscussed_in_filing Cybersecurity
topic_mentionAVXLdiscussed_in_filing Trusted Computing
topic_mentionAVXLdiscussed_in_filing Blockchain & Crypto
topic_mentionAVXLdiscussed_in_filing Autonomous Vehicles
topic_mentionAVXLdiscussed_in_filing Regulation
topic_mentionAVXLdiscussed_in_filing Healthcare & Bio
topic_mentionAVXLdiscussed_in_filing Platform & Ecosystem
topic_mentionAVXLdiscussed_in_filing Sovereign & Government
topic_mentionAVXLdiscussed_in_filing Artificial Intelligence
topic_mentionAVXLdiscussed_in_filing Cybersecurity

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2025-11-252025-09-300001731122-25-001596EDGAR76K words
2024-12-232024-09-300001731122-24-002041EDGAR—
2023-11-272023-09-300001731122-23-002197EDGAR—
2022-11-282022-09-300001731122-22-002062EDGAR—
2021-11-242021-09-300001731122-21-002062EDGAR—
2020-12-282020-09-300001731122-20-001338EDGAR—
2019-12-162019-09-300001731122-19-000784EDGAR—
2018-12-122018-09-300001615774-18-014328EDGAR—
2017-12-112017-09-300001615774-17-007272EDGAR—
2016-12-142016-09-300001615774-16-008914EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2026-02-092025-12-310001731122-26-000200EDGAR21K words
2025-08-122025-06-300001731122-25-001105EDGAR—
2025-05-132025-03-310001731122-25-000724EDGAR—
2025-02-122024-12-310001731122-25-000205EDGAR—
2024-08-062024-06-300001731122-24-001207EDGAR—
2024-05-092024-03-310001731122-24-000760EDGAR—
2024-02-072023-12-310001731122-24-000206EDGAR—
2023-08-082023-06-300001731122-23-001412EDGAR—
2023-05-092023-03-310001731122-23-000845EDGAR—
2023-02-072022-12-310001731122-23-000152EDGAR—
2022-08-092022-06-300001731122-22-001301EDGAR—
2022-05-102022-03-310001731122-22-000851EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-250001731122-26-000482EDGAR1K words
2026-02-250001731122-26-000305EDGAR—
2026-02-090001731122-26-000193EDGAR—
2025-11-250001731122-25-001591EDGAR—
2025-11-140001731122-25-001536EDGAR—
2025-07-280001731122-25-001033EDGAR—
2025-07-030001731122-25-000935EDGAR—
2025-06-130001731122-25-000878EDGAR—
2024-07-300001731122-24-001160EDGAR—
2024-06-210001731122-24-001003EDGAR—

242 total filings indexed. 210 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

FDMT — 4D Molecular Therapeutics, Inc. APTN — ADAPTIN BIO, INC. ADMA — ADMA BIOLOGICS, INC. AGEN — AGENUS INC AIM — AIM ImmunoTech Inc. AMGN — AMGEN INC ABPO — Abpro Holdings, Inc. ABOS — Acumen Pharmaceuticals, Inc.

Tags

alzheimer's-disease parkinson's-disease rett-syndrome fragile-x-syndrome schizophrenia neurodegenerative-diseases neurodevelopmental-diseases rare-diseases mixed-model-for-repeated-measures-(mmrm) positron-emission-tomography-(pet)-imaging machine-learning/ai-genomic-analysis

Company Identity

CIK0001314052
TickerAVXL
ExchangeNasdaq
SIC2836: Biological Products, (No Diagnostic Substances)

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: ee1b989b33d3c83459b4ca64a067e60b918b83802cc7faf2737129614c77e1f8
parent: eb7d6013ce35883355a054119244d8d5150b8b9cb912730120bc9cd854bd781c
content hash: dc0d15b7aa30cf9dd2f5432ae6c2a7454bb52407f59a8a05622698a32b123e38
signed: 2026-04-13T04:43:49.773Z
sources: 22 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf